← Back to Screener
Precigen, Inc. Common Stock (PGEN)
Price$4.11
Favorite Metrics
Price vs S&P 500 (26W)18.82%
Price vs S&P 500 (4W)11.85%
Market Capitalization$1.41B
All Metrics
Book Value / Share (Quarterly)$0.06
P/TBV (Annual)83.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-28.86%
Cash Flow / Share (Quarterly)$-0.25
Price vs S&P 500 (YTD)-8.92%
Gross Margin (TTM)50.20%
Net Profit Margin (TTM)-2588.21%
EPS (TTM)$-0.82
10-Day Avg Trading Volume3.08M
EPS Excl Extra (TTM)$-0.82
Revenue Growth (5Y)-37.70%
EPS (Annual)$-0.80
ROI (Annual)-219.70%
Gross Margin (Annual)50.20%
Net Profit Margin (5Y Avg)-1576.92%
Cash / Share (Quarterly)$0.28
Revenue Growth QoQ (YoY)283.61%
ROA (Last FY)-161.18%
Revenue Growth TTM (YoY)146.73%
EBITD / Share (TTM)$-0.79
ROE (5Y Avg)-306.45%
Operating Margin (TTM)-1141.13%
Cash Flow / Share (Annual)$-0.25
P/B Ratio67.36x
P/B Ratio (Quarterly)70.73x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)151.96x
Net Interest Coverage (TTM)-383.42x
ROA (TTM)-179.85%
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)3.09x
Quick Ratio (Quarterly)2.74x
3-Month Avg Trading Volume4.72M
52-Week Price Return190.51%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.05
P/S Ratio (Annual)145.46x
Asset Turnover (Annual)0.06x
52-Week High$5.46
Operating Margin (5Y Avg)-1421.40%
EPS Excl Extra (Annual)$-0.80
CapEx CAGR (5Y)-23.33%
Tangible BV CAGR (5Y)58.01%
26-Week Price Return27.56%
Quick Ratio (Annual)2.74x
13-Week Price Return-9.75%
Total Debt / Equity (Annual)4.46x
Current Ratio (Quarterly)3.09x
Enterprise Value$1,471.576
Revenue / Share Growth (5Y)-45.06%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)-30.25%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)21.00x
Pretax Margin (Annual)-2588.18%
Cash / Share (Annual)$0.28
3-Month Return Std Dev93.85%
Gross Margin (5Y Avg)35.84%
Net Income / Employee (TTM)$-2
ROE (Last FY)-1198.61%
Net Interest Coverage (Annual)-73.99x
EPS Basic Excl Extra (Annual)$-0.80
Receivables Turnover (TTM)4.00x
Total Debt / Equity (Quarterly)4.46x
EPS Incl Extra (TTM)$-0.82
Receivables Turnover (Annual)4.00x
ROI (TTM)-254.26%
P/S Ratio (TTM)145.46x
Pretax Margin (5Y Avg)-1694.33%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.05
Price vs S&P 500 (52W)155.42%
Year-to-Date Return-4.78%
5-Day Price Return-4.56%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-64.82%
Net Profit Margin (Annual)-2588.21%
Month-to-Date Return2.84%
Cash Flow / Share (TTM)$-0.34
EBITD / Share (Annual)$-0.79
Operating Margin (Annual)-1141.13%
LT Debt / Equity (Annual)4.46x
ROI (5Y Avg)-101.04%
LT Debt / Equity (Quarterly)4.46x
EPS Basic Excl Extra (TTM)$-0.82
P/TBV (Quarterly)83.42x
P/B Ratio (Annual)70.73x
Inventory Turnover (TTM)21.13x
Pretax Margin (TTM)-2588.18%
Book Value / Share (Annual)$0.06
Price vs S&P 500 (13W)-12.62%
Beta1.09x
P/FCF (Annual)61.46x
Revenue / Share (TTM)$0.03
ROE (TTM)-858.93%
52-Week Low$1.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PGENPrecigen, Inc. Common Stock | 145.46x | 146.73% | 50.20% | — | $4.11 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Precigen Inc develops synthetic biology solutions and engineered gene programs for diverse applications across multiple industries. The company commercializes its technologies through exclusive strategic partnerships, generating revenue from technology access fees, royalties, and milestones. Operations are organized into two reportable segments: Biopharmaceuticals and Exemplar.